6results about How to "Regulatory activity" patented technology

The invention belongs to the field of pharmaceutical preparations. The invention relates to lipid nanoparticles modified by probiotic coupled galactose and coated with diammonium glycyrrhizinate, L-arginine and copper tannic acid nano enzyme as well as a preparation method and application of the lipid nanoparticles. The lipid nanoparticles prepared by coupling and wrapping the diammonium glycyrrhizinate, the L-arginine and the copper tannic acid nano-enzyme with the probiotics have good biocompatibility, the preparation method is simple, the particle size distribution of the nanoparticles is uniform, the half-life period of a medicine circulating in a body can be prolonged, the inherent beneficial functions of the probiotics are cooperated, and the bioavailability of the medicine is improved. The potential application value is realized in the fields of treating the metabolic dysfunction related steatohepatitis and the like.

The application discloses a kind of adjustable defect sub-nanometer gold load nickel iron composite photoanode catalyst, preparation method and application, deionized water is introduced into nitrogen and is deoxidized, multi-walled carbon nanotube treated by strong acid is placed in deionized water after deoxidation, after ultrasonic dispersion is uniform, together with FeCl2, NiCl2, HMT and ammonium fluoride is added into reaction kettle, reaction is carried out at 120 DEG C for 6 hours, after cooling, it is taken out, using deionized water is filtered, washed after, HAuCl4 is quickly added, sealed and is stirred in dark room, after reaction is finished, it is filtered, washed, nitrogen is dried at room temperature and is preserved in oxygen-free atmosphere.The application is synthesized Au / NiFe (hydroxyl) oxide / CNT composite catalyst by in-situ oxidation technology one step.The method can be simultaneously controlled on the basis of heterojunction Defects, the synergistic effect of both makes the catalyst performance be further optimized.Synthesis method is simple and direct, and catalytic effect is obviously improved.

This invention provides a catalyst coated with a non-precious metal coating on a support and its preparation method. The invention also relates to the application of this non-precious metal coated-supported catalyst in the catalytic oxidation treatment of volatile organic compounds (VOCs). The catalyst of this invention has high mechanical strength, good coating wear resistance, and is not easily detached. Furthermore, the catalyst exhibits strong hydrothermal stability, good catalytic degradation performance of volatile organic compounds, and a long service life, making it particularly suitable for the treatment of VOCs containing sulfides.

This invention relates to novel compounds and their use as pharmaceuticals, more specifically for the prevention or treatment of diseases mediated by cGAS activity, particularly for the prevention or treatment of inflammatory conditions or cancer. The invention also relates to methods for preventing or treating said diseases, the methods comprising using the novel compounds. The invention further relates to pharmaceutical compositions or formulations of the novel compounds and their use as pharmaceuticals, more preferably for the prevention or treatment of diseases mediated by cGAS activity, particularly for the prevention or treatment of inflammatory conditions or cancer. The invention also relates to methods for preparing the compounds.

The present disclosure relates to compounds of Formula (I): and prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are useful for modulating DNA polymerase theta activity and for the treatment of conditions involving DNA polymerase theta activity, such as cancer.

The application belongs to the technical field of biology and particularly relates to application of ISL2 in regulating melatonin synthesis. The application discloses that ISL2 can be combined with a melatonin synthesis rate-limiting enzyme AANAT gene promoter, so as to regulate activity of the AANAT promoter, further regulate an expression amount of AANAT, and finally realize regulation of melatonin synthesis.